REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Circadian Reset Protocol

Sleep Optimizationintermediate
32
Share
Peptides

3

Avg Daily mcg

3,000

Level

intermediate

Added

May 16, 2026

Overview

The Circadian Reset Protocol is an intermediate-level sleep optimization stack engineered to restore disrupted circadian rhythms, deepen sleep architecture, and promote neurological recovery during rest. By combining DSIP, Selank, and Epithalon, this protocol addresses the three primary drivers of poor sleep: disrupted delta-wave signaling, elevated nighttime anxiety, and dysregulated melatonin production. DSIP (Delta Sleep-Inducing Peptide) at 200mcg daily is a neuropeptide that modulates sleep architecture by promoting slow-wave (stage 3-4) sleep without the sedative hangover of pharmaceutical sleep aids. DSIP works through the hypothalamic sleep-wake axis, normalizing sleep onset latency and increasing the proportion of restorative deep sleep. Research has shown DSIP to be particularly effective for individuals with stress-related insomnia and disrupted sleep-wake cycles from shift work or travel. Selank at 300mcg daily is an anxiolytic heptapeptide derived from the naturally occurring immunomodulatory peptide tuftsin. It reduces GABAergic anxiety and calms overactive evening cortisol without cognitive impairment or dependency. By quieting the hypervigilant nervous system that keeps many people awake at night, Selank creates the neurochemical conditions necessary for natural sleep onset. It also enhances BDNF expression, supporting memory consolidation during sleep. Epithalon at 5000mcg every other day restores pineal gland function and normalizes endogenous melatonin secretion. Rather than supplementing exogenous melatonin (which can downregulate natural production), Epithalon stimulates the pineal gland to produce melatonin at physiologically appropriate times, re-anchoring the circadian clock. Protocol Notes: DSIP and Selank are best administered 60-90 minutes before desired sleep onset. Epithalon can be taken in the morning or evening on alternating days. This stack is suited for professionals dealing with high-stress schedules, frequent travelers crossing time zones, shift workers, or anyone whose natural sleep rhythm has been disrupted. A typical cycle runs 30-60 days. Users often report vivid dreaming, easier morning waking, and significantly improved daytime energy within the first two weeks.

Dosing Protocol

200 mcg

per dose

300 mcg

per dose

Epithalon

Every other day

Read more about Epithalon →

5,000 mcg

per dose

Goals & Evidence

Evidence tier:community

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.